Travere Therapeutics, Inc. TVTX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Travere Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s retained earnings?
- Travere Therapeutics, Inc. (TVTX) reported retained earnings of -$1.51B in Q1 2026.
- How has Travere Therapeutics, Inc.'s retained earnings changed year-over-year?
- Travere Therapeutics, Inc.'s retained earnings decreased by 1.4% year-over-year, from -$1.49B to -$1.51B.
- What is the long-term trend for Travere Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Travere Therapeutics, Inc.'s retained earnings has grown at a 20.2% compound annual growth rate (CAGR), from -$585.88M to -$1.47B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.